Mixed Phase III data for etrolizumab in moderately to severely active ulcerative colitis

In the HIBISCUS I induction study, in people without prior anti-TNF treatment, etrolizumab met the primary endpoint of inducing remission versus placebo, however, in the HIBISCUS II induction study and the LAUREL maintenance study, the primary endpoints were not met.